{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T10:42:28Z","timestamp":1761129748193},"reference-count":77,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Semin Thromb Hemost"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>In the ongoing pandemic of coronavirus disease 2019 (COVID-19), the novel virus SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) is infecting a na\u00efve population. The innate immunity of the infected patient is unable to mount an effective defense, resulting in a severe illness with substantial morbidity and mortality. As most treatment modalities including antivirals and anti-inflammatory agents are mostly ineffective, an immunological approach is needed. The mechanism of innate immunity to this viral illness is not fully understood. Passive immunity becomes an important avenue for the management of these patients. In this article, the immune responses of COVID-19 patients are reviewed. As SARS-CoV-2 has many characteristics in common with two other viruses, SARS-CoV that cause severe acute respiratory syndrome (SARS) and MERS-CoV (Middle East respiratory syndrome coronavirus) that causes Middle East respiratory syndrome (MERS), the experiences learned from the use of passive immunity in treatment can be applied to COVID-19. The immune response includes the appearance of immunoglobulin M followed by immunoglobulin G and neutralizing antibodies. Convalescent plasma obtained from patients recovered from the illness with high titers of neutralizing antibodies was successful in treating many COVID-19 patients. The factors that determine responses as compared with those seen in SARS and MERS are also reviewed. As there are no approved vaccines against all three viruses, it remains a challenge in the ongoing development for an effective vaccine for COVID-19.<\/jats:p>","DOI":"10.1055\/s-0040-1712157","type":"journal-article","created":{"date-parts":[[2020,6,11]],"date-time":"2020-06-11T22:41:21Z","timestamp":1591915281000},"page":"796-803","source":"Crossref","is-referenced-by-count":8,"title":["Passive Immunity for Coronavirus Disease 2019: A Commentary on Therapeutic Aspects Including Convalescent Plasma"],"prefix":"10.1055","volume":"46","author":[{"given":"Paul F.","family":"Lindholm","sequence":"additional","affiliation":[{"name":"Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Glenn","family":"Ramsey","sequence":"additional","affiliation":[{"name":"Department of Pathology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hau C.","family":"Kwaan","sequence":"additional","affiliation":[{"name":"Division of Hematology-Oncology, Department of Medicine, Feinberg School of Medicine, Northwestern University, Chicago, Illinois"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2020,6,11]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"2000547","DOI":"10.1183\/13993003.00547-2020","article-title":"Comorbidity and its impact on 1590 patients with Covid-19 in China: a nationwide analysis","author":"W J Guan","year":"2020","journal-title":"Eur Respir J"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2002032","article-title":"Clinical characteristics of coronavirus disease 2019 in China","author":"W J Guan","year":"2020","journal-title":"N Engl J Med"},{"issue":"01","key":"ref3","first-page":"11","article-title":"The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status","volume":"7","author":"Y R Guo","year":"2020","journal-title":"Mil Med Res"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin","volume":"579","author":"P Zhou","year":"2020","journal-title":"Nature"},{"issue":"02","key":"ref5","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1111\/resp.13196","article-title":"MERS, SARS and other coronaviruses as causes of pneumonia","volume":"23","author":"Y Yin","year":"2018","journal-title":"Respirology"},{"issue":"04","key":"ref6","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1016\/j.coi.2005.05.009","article-title":"Pathogenesis of severe acute respiratory syndrome","volume":"17","author":"Y L Lau","year":"2005","journal-title":"Curr Opin Immunol"},{"issue":"04","key":"ref7","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/jmv.25685","article-title":"Coronavirus infections and immune responses","volume":"92","author":"G Li","year":"2020","journal-title":"J Med Virol"},{"issue":"05","key":"ref8","first-page":"1","article-title":"Novel 2019 coronavirus SARS-CoV-2 (COVID-19): an updated overview for emergency clinicians","volume":"22","author":"A L Giwa","year":"2020","journal-title":"Emerg Med Pract"},{"issue":"01","key":"ref9","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1186\/s40249-020-00646-x","article-title":"Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review","volume":"9","author":"S P Adhikari","year":"2020","journal-title":"Infect Dis Poverty"},{"issue":"03","key":"ref10","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1136\/thorax.2003.012658","article-title":"Role of lopinavir\/ritonavir in the treatment of SARS: initial virological and clinical findings","volume":"59","author":"C M Chu","year":"2004","journal-title":"Thorax"},{"issue":"01","key":"ref11","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s13063-019-3846-x","article-title":"Treatment of Middle East respiratory syndrome with a combination of lopinavir\/ritonavir and interferon-\u03b21b (MIRACLE trial): statistical analysis plan for a recursive two-stage group sequential randomized controlled trial","volume":"21","author":"Y M Arabi","year":"2020","journal-title":"Trials"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"104762","DOI":"10.1016\/j.antiviral.2020.104762","article-title":"Of chloroquine and COVID-19","volume":"177","author":"F Touret","year":"2020","journal-title":"Antiviral Res"},{"issue":"01","key":"ref13","doi-asserted-by":"crossref","first-page":"72","DOI":"10.5582\/bst.2020.01047","article-title":"Breakthrough: chloroquine phosphate has shown apparent efficacy in treatment of COVID-19 associated pneumonia in clinical studies","volume":"14","author":"J Gao","year":"2020","journal-title":"Biosci Trends"},{"issue":"01","key":"ref14","first-page":"1","article-title":"Immune responses in COVID-19 and potential vaccines: Lessons learned from SARS and MERS epidemic","volume":"38","author":"E Prompetchara","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"04","key":"ref15","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s00281-016-0558-0","article-title":"The host immune response in respiratory virus infection: balancing virus clearance and immunopathology","volume":"38","author":"A H Newton","year":"2016","journal-title":"Semin Immunopathol"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"C Huang","year":"2020","journal-title":"Lancet"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.1016\/S0140-6736(03)13410-1","article-title":"Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong","volume":"361","author":"C A Donnelly","year":"2003","journal-title":"Lancet"},{"issue":"04","key":"ref18","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S1526-0542(03)00088-5","article-title":"Severe acute respiratory syndrome (SARS) in children: epidemiology, presentation and management","volume":"4","author":"T F Leung","year":"2003","journal-title":"Paediatr Respir Rev"},{"issue":"01","key":"ref19","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1365-2249.2004.02415.x","article-title":"Plasma inflammatory cytokines and chemokines in severe acute respiratory syndrome","volume":"136","author":"C K Wong","year":"2004","journal-title":"Clin Exp Immunol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.cyto.2018.01.025","article-title":"MERS-CoV infection in humans is associated with a pro-inflammatory Th1 and Th17 cytokine profile","volume":"104","author":"W H Mahallawi","year":"2018","journal-title":"Cytokine"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41586-020-2008-3","article-title":"A new coronavirus associated with human respiratory disease in China","volume":"579","author":"F Wu","year":"2020","journal-title":"Nature"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1172\/JCI126363","article-title":"IFN-I response timing relative to virus replication determines MERS coronavirus infection outcomes","volume":"130","author":"R Channappanavar","year":"2019","journal-title":"J Clin Invest"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1007\/s12026-014-8534-z","article-title":"T cell-mediated immune response to respiratory coronaviruses","volume":"59","author":"R Channappanavar","year":"2014","journal-title":"Immunol Res"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"995","DOI":"10.1016\/S0140-6736(15)60454-8","article-title":"Middle East respiratory syndrome","volume":"386","author":"A Zumla","year":"2015","journal-title":"Lancet"},{"issue":"05","key":"ref25","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s00281-017-0629-x","article-title":"Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology","volume":"39","author":"R Channappanavar","year":"2017","journal-title":"Semin Immunopathol"},{"issue":"12","key":"ref26","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1038\/nri1732","article-title":"Immunopathogenesis of coronavirus infections: implications for SARS","volume":"5","author":"S Perlman","year":"2005","journal-title":"Nat Rev Immunol"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/5584_2015_110","article-title":"Pathophysiology of clinical symptoms in acute viral respiratory tract infections","volume":"857","author":"E Kuchar","year":"2015","journal-title":"Adv Exp Med Biol"},{"issue":"05","key":"ref28","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/s41564-019-0392-y","article-title":"Antibody responses to viral infections: a structural perspective across three different enveloped viruses","volume":"4","author":"C D Murin","year":"2019","journal-title":"Nat Microbiol"},{"issue":"42","key":"ref29","doi-asserted-by":"crossref","first-page":"11931","DOI":"10.1073\/pnas.1609316113","article-title":"Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus","volume":"113","author":"W He","year":"2016","journal-title":"PNAS"},{"issue":"01","key":"ref30","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1080\/22221751.2020.1742076","article-title":"Generation of neutralizing and non-neutralizing monoclonal antibodies against H7N9 influenza virus","volume":"9","author":"F Yang","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"10","key":"ref31","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1016\/j.tim.2015.07.005","article-title":"Antiviral monoclonal antibodies: can they be more than simple neutralizing agents?","volume":"23","author":"M Pelegrin","year":"2015","journal-title":"Trends Microbiol"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.molimm.2020.03.005","article-title":"Drivers and regulators of humoral innate immune responses to infection and cancer","volume":"121","author":"D Kumar","year":"2020","journal-title":"Mol Immunol"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.3332\/ecancer.2020.1023","article-title":"COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting?","volume":"14","author":"B Russell","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/S0140-6736(20)30317-2","article-title":"Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury","volume":"395","author":"C D Russell","year":"2020","journal-title":"Lancet"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0140-6736(20)30361-5","article-title":"On the use of corticosteroids for 2019-nCoV pneumonia","volume":"395","author":"L Shang","year":"2020","journal-title":"Lancet"},{"key":"ref36","doi-asserted-by":"publisher","DOI":"10.5694\/mja2.50577","article-title":"Corticosteroid treatment of patients with coronavirus disease 2019 (COVID-19)","author":"L Zha","year":"2020","journal-title":"Med J Aust"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.antiviral.2016.11.006","article-title":"T-cell immunity of SARS-CoV: implications for vaccine development against MERS-CoV","volume":"137","author":"W J Liu","year":"2017","journal-title":"Antiviral Res"},{"issue":"06","key":"ref38","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1086\/500469","article-title":"Two-year prospective study of the humoral immune response of patients with severe acute respiratory syndrome","volume":"193","author":"W Liu","year":"2006","journal-title":"J Infect Dis"},{"issue":"10","key":"ref39","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.7150\/ijbs.45123","article-title":"Perspectives on therapeutic neutralizing antibodies against the novel coronavirus SARS-CoV-2","volume":"16","author":"G Zhou","year":"2020","journal-title":"Int J Biol Sci"},{"key":"ref40","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmii.2020.03.015","article-title":"Duration of serum neutralizing antibodies for SARS-CoV-2: lessons from SARS-CoV infection","author":"Q Lin","year":"2020","journal-title":"J Microbiol Immunol Infect"},{"issue":"02","key":"ref41","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1080\/14728222.2017.1271415","article-title":"MERS-CoV spike protein: a key target for antivirals","volume":"21","author":"L Du","year":"2017","journal-title":"Expert Opin Ther Targets"},{"issue":"01","key":"ref42","first-page":"10","article-title":"Perspectives on monoclonal antibody therapy as potential therapeutic intervention for Coronavirus disease-19 (COVID-19)","volume":"38","author":"B Shanmugaraj","year":"2020","journal-title":"Asian Pac J Allergy Immunol"},{"issue":"06","key":"ref43","doi-asserted-by":"crossref","first-page":"591","DOI":"10.2217\/imt.15.33","article-title":"Human neutralizing antibodies against MERS coronavirus: implications for future immunotherapy","volume":"7","author":"X C Tang","year":"2015","journal-title":"Immunotherapy"},{"issue":"05","key":"ref44","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1080\/21645515.2015.1021527","article-title":"Optimization of antigen dose for a receptor-binding domain-based subunit vaccine against MERS coronavirus","volume":"11","author":"J Tang","year":"2015","journal-title":"Hum Vaccin Immunother"},{"issue":"01","key":"ref45","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1080\/22221751.2020.1729069","article-title":"Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody","volume":"9","author":"X Tian","year":"2020","journal-title":"Emerg Microbes Infect"},{"issue":"02","key":"ref46","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1378\/chest.12-2907","article-title":"Hyperimmune IV immunoglobulin treatment: a multicenter double-blind randomized controlled trial for patients with severe 2009 influenza A(H1N1) infection","volume":"144","author":"I FN Hung","year":"2013","journal-title":"Chest"},{"issue":"02","key":"ref47","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s00134-020-05943-5","article-title":"Critical care management of adults with community-acquired severe respiratory viral infection","volume":"46","author":"Y M Arabi","year":"2020","journal-title":"Intensive Care Med"},{"key":"ref48","first-page":"138745","article-title":"Deployment of convalescent plasma for the prevention and treatment of COVID-19","author":"E M Bloch","year":"2020","journal-title":"J Clin Invest"},{"key":"ref49","first-page":"37","volume-title":"Methods to study viruses","author":"S Payne","year":"2017"},{"issue":"08","key":"ref50","doi-asserted-by":"crossref","first-page":"599","DOI":"10.7326\/0003-4819-145-8-200610170-00139","article-title":"Meta-analysis: convalescent blood products for Spanish influenza pneumonia: a future H5N1 treatment?","volume":"145","author":"T C Luke","year":"2006","journal-title":"Ann Intern Med"},{"key":"ref51","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1001\/jama.1919.26110010013009d","article-title":"Treatment of influenzal pneumonia with plasma of convalescent patients","volume":"72","author":"J J O'Malley","year":"1919","journal-title":"J Am Med Assoc"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1001\/jama.1919.02610100017007","article-title":"Treatment of influenzal pneumonia by the use of convalescent human serum: Second report","volume":"72","author":"L W McGuire","year":"1919","journal-title":"J Am Med Assoc"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1056\/NEJM192008051830609","article-title":"The use of the serum of convalescents in the treatment of influenza pneumonia: a summary of the results in a series of one hundred and one cases","volume":"183","author":"G Sanborn","year":"1920","journal-title":"Boston Med Surg J"},{"issue":"01","key":"ref54","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/infdis\/jiu396","article-title":"The effectiveness of convalescent plasma and hyperimmune immunoglobulin for the treatment of severe acute respiratory infections of viral etiology: a systematic review and exploratory meta-analysis","volume":"211","author":"J Mair-Jenkins","year":"2015","journal-title":"J Infect Dis"},{"issue":"04","key":"ref55","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1093\/cid\/ciq106","article-title":"Convalescent plasma treatment reduced mortality in patients with severe pandemic influenza A (H1N1) 2009 virus infection","volume":"52","author":"I F Hung","year":"2011","journal-title":"Clin Infect Dis"},{"issue":"06","key":"ref56","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/S2213-2600(17)30174-1","article-title":"Immune plasma for the treatment of severe influenza: an open-label, multicentre, phase 2 randomised study","volume":"5","author":"J H Beigel","year":"2017","journal-title":"Lancet Respir Med"},{"issue":"11","key":"ref57","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1016\/S2213-2600(19)30199-7","article-title":"Anti-influenza immune plasma for the treatment of patients with severe influenza A: a randomised, double-blind, phase 3 trial","volume":"7","author":"J H Beigel","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"01","key":"ref58","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1007\/s10096-004-1271-9","article-title":"Use of convalescent plasma therapy in SARS patients in Hong Kong","volume":"24","author":"Y Cheng","year":"2005","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"01","key":"ref59","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.16377","article-title":"Advances in knowledge of inhibitor formation in severe haemophilia A","volume":"189","author":"M Cormier","year":"2020","journal-title":"Br J Haematol"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1186\/s40064-015-1490-9","article-title":"Feasibility, safety, clinical, and laboratory effects of convalescent plasma therapy for patients with Middle East respiratory syndrome coronavirus infection: a study protocol","volume":"4","author":"Y Arabi","year":"2015","journal-title":"Springerplus"},{"issue":"07","key":"ref61","doi-asserted-by":"crossref","first-page":"617","DOI":"10.3851\/IMP3243","article-title":"Challenges of convalescent plasma infusion therapy in Middle East respiratory coronavirus infection: a single centre experience","volume":"23","author":"J H Ko","year":"2018","journal-title":"Antivir Ther"},{"key":"ref62","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2004168117","article-title":"Effectiveness of convalescent plasma therapy in severe COVID-19 patients","author":"K Duan","year":"2020","journal-title":"Proc Natl Acad Sci USA"},{"key":"ref63","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.4783","article-title":"Treatment of 5 critically ill patients with COVID-19 with convalescent plasma","author":"C Shen","year":"2020","journal-title":"JAMA"},{"key":"ref64","doi-asserted-by":"publisher","DOI":"10.1111\/vox.12926","article-title":"Collecting and evaluating convalescent plasma for COVID-19 treatment: why and how","author":"P Tiberghien","year":"2020","journal-title":"Vox Sang"},{"issue":"02","key":"ref65","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/jmv.20431","article-title":"A serological survey on neutralizing antibody titer of SARS convalescent sera","volume":"77","author":"J S Zhang","year":"2005","journal-title":"J Med Virol"},{"issue":"03","key":"ref66","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1086\/653940","article-title":"Effect of clinical and virological parameters on the level of neutralizing antibody against pandemic influenza A virus H1N1 2009","volume":"51","author":"I F Hung","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"02","key":"ref67","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.diagmicrobio.2017.07.006","article-title":"Serologic responses of 42 MERS-coronavirus-infected patients according to the disease severity","volume":"89","author":"J H Ko","year":"2017","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"01","key":"ref68","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1186\/s12985-018-1105-5","article-title":"Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies","volume":"15","author":"E Nurtop","year":"2018","journal-title":"Virol J"},{"issue":"01","key":"ref69","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s12985-019-1118-8","article-title":"Correction to: Combination of ELISA screening and seroneutralisation tests to expedite Zika virus seroprevalence studies","volume":"16","author":"E Nurtop","year":"2019","journal-title":"Virol J"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"2991","DOI":"10.3389\/fmicb.2018.02991","article-title":"Viral-induced enhanced disease illness","volume":"9","author":"M K Smatti","year":"2018","journal-title":"Front Microbiol"},{"issue":"03","key":"ref72","doi-asserted-by":"crossref","first-page":"313","DOI":"10.4014\/jmb.2003.03011","article-title":"Current status of epidemiology, diagnosis, therapeutics, and vaccines for novel coronavirus disease 2019 (COVID-19)","volume":"30","author":"D G Ahn","year":"2020","journal-title":"J Microbiol Biotechnol"},{"issue":"02","key":"ref73","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/j.bbrc.2004.09.106","article-title":"Receptor-binding domain of SARS-CoV spike protein induces highly potent neutralizing antibodies: implication for developing subunit vaccine","volume":"324","author":"Y He","year":"2004","journal-title":"Biochem Biophys Res Commun"},{"issue":"06","key":"ref74","doi-asserted-by":"crossref","first-page":"4050","DOI":"10.4049\/jimmunol.173.6.4050","article-title":"Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines","volume":"173","author":"Y He","year":"2004","journal-title":"J Immunol"},{"issue":"09","key":"ref75","doi-asserted-by":"crossref","first-page":"4638","DOI":"10.1128\/JVI.78.9.4638-4645.2004","article-title":"Generation and characterization of DNA vaccines targeting the nucleocapsid protein of severe acute respiratory syndrome coronavirus","volume":"78","author":"T W Kim","year":"2004","journal-title":"J Virol"},{"issue":"01","key":"ref76","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1089\/088282403763635465","article-title":"Antibody-dependent enhancement of virus infection and disease","volume":"16","author":"S M Tirado","year":"2003","journal-title":"Viral Immunol"},{"issue":"02","key":"ref77","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.bbrc.2014.07.090","article-title":"Antibody-dependent SARS coronavirus infection is mediated by antibodies against spike proteins","volume":"451","author":"S F Wang","year":"2014","journal-title":"Biochem Biophys Res Commun"},{"issue":"05","key":"ref78","first-page":"94","article-title":"Molecular mechanism for antibody-dependent enhancement of coronavirus entry","volume":"94","author":"Y Wan","year":"2020","journal-title":"J Virol"}],"container-title":["Seminars in Thrombosis and Hemostasis"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/s-0040-1712157.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,20]],"date-time":"2020-10-20T22:33:03Z","timestamp":1603233183000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/s-0040-1712157"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,11]]},"references-count":77,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2020,10,20]]},"published-print":{"date-parts":[[2020,10]]}},"URL":"https:\/\/doi.org\/10.1055\/s-0040-1712157","relation":{},"ISSN":["0094-6176","1098-9064"],"issn-type":[{"value":"0094-6176","type":"print"},{"value":"1098-9064","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,11]]}}}